OBJECTIVE: To identify whether therapeutic hypothermia in newborns with hypoxic ischemic encephalopathy affects gentamicin pharmacokinetics. STUDY DESIGN: Retrospective case-control study consisting of 16 neonates who underwent therapeutic hypothermia and received gentamicin with interpretable peak and trough serum levels obtained during the period of cooling and at steady state; comparator group consisting of 7 neonates met the criteria but did not undergo therapeutic hypothermia. RESULTS: Significant differences in gentamicin pharmacokinetics were noted between the therapeutic hypothermia group and the comparator group in elimination rate constant (0.08/h versus 0.11/h; P < 0.01), elimination half-life (9.16 hours versus 6.56 hours; P < 0.01), and clearance (0.04 L/kg.h(-1) versus 0.05 L/kg.h(-1); P < 0.01), respectively. Higher gentamicin trough serum concentrations were seen with the therapeutic hypothermia group (1.68 mcg/mL versus 0.77 mcg/mL; P < 0.01). CONCLUSIONS: Therapeutic hypothermia is associated with alterations in gentamicin pharmacokinetics, reducing gentamicin clearance by 25.5% in neonates with hypoxic ischemic encephalopathy, which may result in increased trough serum concentrations.
OBJECTIVE: To identify whether therapeutic hypothermia in newborns with hypoxic ischemicencephalopathy affects gentamicin pharmacokinetics. STUDY DESIGN: Retrospective case-control study consisting of 16 neonates who underwent therapeutic hypothermia and received gentamicin with interpretable peak and trough serum levels obtained during the period of cooling and at steady state; comparator group consisting of 7 neonates met the criteria but did not undergo therapeutic hypothermia. RESULTS: Significant differences in gentamicin pharmacokinetics were noted between the therapeutic hypothermia group and the comparator group in elimination rate constant (0.08/h versus 0.11/h; P < 0.01), elimination half-life (9.16 hours versus 6.56 hours; P < 0.01), and clearance (0.04 L/kg.h(-1) versus 0.05 L/kg.h(-1); P < 0.01), respectively. Higher gentamicin trough serum concentrations were seen with the therapeutic hypothermia group (1.68 mcg/mL versus 0.77 mcg/mL; P < 0.01). CONCLUSIONS: Therapeutic hypothermia is associated with alterations in gentamicin pharmacokinetics, reducing gentamicin clearance by 25.5% in neonates with hypoxic ischemicencephalopathy, which may result in increased trough serum concentrations.
Authors: Marcel P H van den Broek; Floris Groenendaal; Antoine C G Egberts; Carin M A Rademaker Journal: Clin Pharmacokinet Date: 2010-05 Impact factor: 6.447
Authors: Kacey B Anderson; Samuel M Poloyac; Patrick M Kochanek; Philip E Empey Journal: Ther Hypothermia Temp Manag Date: 2016-09-13 Impact factor: 1.286
Authors: Yuma A Bijleveld; Timo R de Haan; Hanneke J H van der Lee; Floris Groenendaal; Peter H Dijk; Arno van Heijst; Rogier C J de Jonge; Koen P Dijkman; Henrica L M van Straaten; Monique Rijken; Inge A Zonnenberg; Filip Cools; Alexandra Zecic; Debbie H G M Nuytemans; Anton H van Kaam; Ron A A Mathot Journal: Br J Clin Pharmacol Date: 2016-03-10 Impact factor: 4.335
Authors: Shufan Ge; Ryan J Beechinor; Christoph P Hornik; Joseph F Standing; Kanecia Zimmerman; Michael Cohen-Wolkowiez; Matthew M Laughon; Reese Clark; Daniel Gonzalez Journal: Antimicrob Agents Chemother Date: 2018-08-27 Impact factor: 5.938
Authors: Neel Deferm; Kim V Annink; Ruben Faelens; Michael Schroth; Christian A Maiwald; Loubna El Bakkali; Frank van Bel; Manon J N L Benders; Mirjam M van Weissenbruch; Anja Hagen; Anne Smits; Pieter Annaert; Axel R Franz; Karel Allegaert Journal: Clin Pharmacokinet Date: 2021-02-21 Impact factor: 6.447